Translational Science in Cancer Health Disparities Research Peter Ujhazy, M.D., Ph.D. Program Director Translational Research Program Division of Cancer.

Slides:



Advertisements
Similar presentations
Update on Ovarian Cancer
Advertisements

Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.
Systems Based Practice and Practice Based Learning. How to teach? How to evaluate? Deborah J. DeWaay M.D. Hospitalist/Clerkship Director, General Internal.
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Concordance of HIV surveillance and medical record data: What do CD4 and viral loads not tell us about linkage to HIV care? Charu Sabharwal, MD MPH Medical.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Cancer Clinical Trials:
Developments at The Arkansas Center for Health Improvement Suzanne McCarthy Founding Associate
Panel: Assessing the Value of Biomedical Research from public and patient perspectives NIH SMRB Meeting: October 24, 2013 Elaine K. Gallin, Ph.D. QE Philanthropic.
Funding Priorities: National Cancer Institute Carly Parry, PhD, MSW National Cancer Institute.
Stress Regulation of Tumor Biology Robert T. Croyle, PhD Director Division of Cancer Control and Population Sciences Concept Presentation NCI Board of.
How to Find and Access Clinical Trials New Treatments, No Tricks A Seminar on Minority Participation in Clinical Trials June 15, 2010.
Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.
TYPE 2 TRANSLATIONAL RESEARCH 2009 GRANT PROGRAMS UW Institute for Clinical and Translational Research (ICTR) Community-Academic Partnership Core (CAP)
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Assessing Minority Participation in Clinical Trials: Setting Attainable Goals The Minority and Women Clinical Trials Recruitment Program Department of.
Finding N.E.M.O. Marvin R. Balaan, MD, FCCP System Division Director, Division of Pulmonary and Critical Care Medicine Allegheny Health Network, Pittsburgh.
PhenX-Sickle Cell Disease Project at the National Heart, Lung, and Blood Institute/NIH Ellen M. Werner, Ph.D. Program Director Blood Epidemiology and Clinical.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
Evaluating Tuberculosis Surveillance and Action in an Urban and Rural Setting Kristine Lykens, Ph.D. In collaboration with Anita Kurian, MPH, MBBS Patrick.
Introduction to Basic Science Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.
1 Introduction to Grant Writing Beth Virnig, PhD Haitao Chu, MD, PhD University of Minnesota, School of Public Health December 11, 2013.
ABSTRACT Introduction: HIV infection is growing relatively fast among seniors. Among the clinical implications are that older patients have less ability.
Otis W. Brawley M.D. Director, Georgia Cancer Center Associate Director, Winship Cancer Institute Professor of Hematology, Oncology, and Epidemiology Emory.
CORPORATE INNOVATION AS AN ENGINE FOR CHANGE: Molecular Diagnostics David Okrongly, Ph.D. SVP Molecular Diagnostics Siemens Healthcare.
POWER: Project for an Ontario Women’s Health Evidence-Based Report Card Asma Razzaq Academy Health Annual Research Meeting June 3,
NSF Minority Faculty Development Workshop Alexis Bakos, PhD, MPH, RN,C Chief, Diversity Training Branch Center to Reduce Cancer Health Disparities, NCI.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Management and Development for Health (MDH)
Early Detection of Lung Cancer & Beyond
Part Time “ Detailee ” for the National Cancer Institute (NCI) under the Intergovernmental Personnel Act (IPA) Ron Hays
Slide 1 Community Networks to Reduce Cancer Health Disparities Pre-Application Conference May 26, 2004 Bethesda, MD Kenneth C. Chu, PhD Chief, Disparities.
Measuring Technical Progress and Potential Impact in Real Time Presented at the American Evaluation Association Conference 2009 by Jerald Hage, Wilbur.
The KU Wichita Center for Breast Cancer Survivorship Judy Johnston, MS, RD/LD Research Instructor Department of Preventive Medicine and Public Health,
Data Sources-Cancer Betsy A. Kohler, MPH, CTR Director, Cancer Epidemiology Services New Jersey Department of Health and Senior Services.
Oral Cancer Training Modules Program Sandra J. Maurizio, R.D.H., Ph.D. School of Allied Health College of Applied Sciences and Arts Southern Illinois University,
Co-Director: Rahma Mungia, DDS, MSc.  What is Practice-Based Research Network (PBRN)?  Benefits of Participating in a PBRN  How to Engage Community.
Other Intramural Training Opportunities at NCI Scientific DisciplinesProgram Population-based research, environmental & genetic determinants of cancer.
Results Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool E. Patrozou M.D., E. Christaki M.D., L. Hicks.
Community Networks to Reduce Cancer Health Disparities Community Networks to Reduce Cancer Health Disparities Harold P. Freeman, MD, Director Center to.
Approach or Research Design Randall Duncan Biological Sciences COBRE Grant Writing Workshop January 21, 2015.
The Importance of a Strategic Plan to Eliminate Health Disparities 2008 eHealth Conference June 9, 2008 Yvonne T. Maddox, PhD Deputy Director Eunice Kennedy.
Diversity and the Burden of Cancer David C. Momrow, M.P.H. Senior Vice President of Cancer Control American Cancer Society – Eastern Division January 21,
Introduction to the NIH
Accountable Care Organizations: What is the role of the pathologist? What are the public policy implications?
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
The SARC Sarcoma SPORE: A Unique Collaborative (Ad)venture Raphael E. Pollock, MD, PhD Department of Surgical Oncology Division of Surgery University of.
Smoking and Mental Health Problems in Treatment-Seeking University Students Eric Heiligenstein, M.D. University of Wisconsin-Madison Health Services Stevens.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: AMD in the Age-Related Eye Disease Study Chew EY, Clemons TE, Agrón E, et al;
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
Research Priorities & Trends for NIH in 2003 Claire T. Driscoll Director Technology Transfer Office National Human Genome Research Institute (NHGRI) Research.
CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.
Mortality After Incident Cancer in People With and Without Type 2 Diabetes Featured Article: Craig J. Currie, Ph.D., Chris D. Poole, Ph.D., Sara Jenkins-Jones,
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
GLOBAL ENGAGEMENT OFFICE West Virginia University Health Sciences Center.
Research Directions and Update from the NIA Basil Eldadah Division of Geriatrics and Clinical Gerontology NIA.
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
Science for Global Health: Fostering International Research Collaboration James Herrington, PhD, MPH Director Division of International Relations Fogarty.
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
Biomedical Data Science for Precision Medicine
A one-year audit of topics and domains in the Journal of the American Medical Association and the New England Journal of Medicine1  Steven H Woolf, MD,
CK707 BSc in Medical and Health Sciences
NATIONAL outreach Network
VACS Cancer Core Robert Dubrow, PhD, MD Founding Director
World Health Organization Collaborating Centre for Occupational Health
Overview of Clinical & Translational Penn
Management and Development for Health (MDH)
NAACCR/IACR Combined Annual Conference 6/11/2019, Vancouver, Canada
Presentation transcript:

Translational Science in Cancer Health Disparities Research Peter Ujhazy, M.D., Ph.D. Program Director Translational Research Program Division of Cancer Treatment and Diagnosis National Cancer Institute Professional Development Workshop June 23-24, 2014 Natcher Conference Center NIH Bethesda, MD

Continuum of Biomedical Research Translational research means different things to different people, but it seems important to almost everyone. The Meaning of Translational Research and Why It Matters Steven H. Woolf, MD, MPH JAMA. 2008;299(2):

Continuum of Biomedical Research Translational research means different things to different people, but it seems important to almost everyone. The Meaning of Translational Research and Why It Matters Steven H. Woolf, MD, MPH JAMA. 2008;299(2): Institute of Medicine’s Clinical Research Roundtable; Woolf, 2008; Kon, 2008

T1 = The transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention and their first testing in humans T2 = The translation of results from clinical studies into everyday clinical practice and health decision making T3 = The task of discovering ways to move these findings into the daily care of patient(s) T4 = The challenge of moving scientific knowledge into the public sector and thereby changing people’s everyday lives Institute of Medicine’s Clinical Research Roundtable; Woolf, 2008; Kon, 2008 Definitions

T1 = The transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention and their first testing in humans T2 = The translation of results from clinical studies into everyday clinical practice and health decision making T3 = The task of discovering ways to move these findings into the daily care of patient(s) T4 = The challenge of moving scientific knowledge into the public sector and thereby changing people’s everyday lives Institute of Medicine’s Clinical Research Roundtable; Woolf, 2008; Kon, 2008 Definitions

Translational Research Program (TRP)TRP Division of Cancer Treatment and Diagnosis (DCTD)DCTD National Cancer Institute (NCI)NCI National Institutes of Health (NIH)NIH 9609 Medical Center Drive, Room 3W110, MSC 9726 Rockville, MD Tel: ; Fax: Specialized Programs of Research Excellence (SPORE) SPORE SPORE Web-site:

Translational Research in the SPORE Program Translational research uses knowledge of human biology to develop and test the feasibility of cancer-relevant interventions* in humans AND/OR determines the biological basis for observations made in individuals with cancer or in populations at risk for cancer * The term “interventions” is used in its broadest sense to include molecular assays, imaging techniques, drugs, biological agents, and/or other methodologies applicable to the prevention, early detection, diagnosis, prognosis, and/or treatment of cancer.

SPORE Requirements P50 Specialized Center Grant  Minimum of four research projects including the “required project”  All projects must be translational  Administrative Core  Scientific Collaboration (SC)  Shared Resources Cores:  Biospecimen/pathology: required  Stats, clinical, animal, etc.: optional  Developmental Research Program (DRP)  Career Development Program (CDP)  External Advisory Board Members  Commitment to attend and participate in NCI sponsored meetings/workshops  Minimum Time Commitment:  SPORE director(s): > 2.4 calendar months  Project co-leader: > 0.6 calendar months  Core director: > 0.6 calendar months  DRP/CDP director: > 0.3 calendar months

January 2014, Vol. 21, No. 1

Overall survival of non–small-cell lung cancer patients by time period (Moffitt) Schabath et al, 2014

Overall survival of NSCLC patients by time period and stage (Moffitt) Stage I-II Stage III Stage IV Schabath et al, 2014

Multivariable Cox Proportional Hazard Models for 5 Time Periods Schabath et al, 2014

Survival among the subset of 86 HIV-infected HNC cases with survival data, CD4 at diagnosis, HPV composite status, tumor site, and cancer stage D’Souza et al, 2014

Comparison of HIV-HNC with US-HNC general population D’Souza et al, 2014

PatientsHIV-HNCUS-HNC Male91%68% Median Age50 years62 years Nonwhite49%18% Current smokers61%18% Median survival63 months61 months Comparison of HIV-HNC with US-HNC general population

Conclusion: Risk factors for the development of HNC in patients with HIV infection are similar to the general population, including both HPV-related and tobacco/alcohol-related HNC.